4th iPSC Drug Development and Manufacturing Summit

Temi della conferenza
With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment.

Professional congress organizer (PCO)
Hanson Wade

Annotazioni
URL:
Brochure: https://go.evvnt.com/2453698-3?pid=4832

Speakers: Allen Feng, Founder and Chief Scientific Officer, HebeCell, and more

https://go.evvnt.com/2453698-2?pid=4832

Mr. Elliot Karmel